Dutrebis Patent Expiration

Dutrebis is a drug owned by Merck Sharp And Dohme Corp. It is protected by 9 US drug patents filed from 2015 to 2017. Out of these, 2 drug patents are active and 7 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 11, 2029. Details of Dutrebis's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US7754731 Potassium salt of an HIV integrase inhibitor
Mar, 2029

(4 years from now)

Active
US7169780 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2023

(1 year, 12 days ago)

Expired
US7820660 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(1 year, 5 months ago)

Expired
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7754731

(Pediatric)

Potassium salt of an HIV integrase inhibitor
Sep, 2029

(4 years from now)

Active
US7169780

(Pediatric)

N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2024

(6 months ago)

Expired
US7217713

(Pediatric)

N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(1 year, 5 months ago)

Expired
US7435734

(Pediatric)

N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(1 year, 5 months ago)

Expired
US7217713 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(1 year, 11 months ago)

Expired
US7435734 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(1 year, 11 months ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dutrebis's patents.

Given below is the list of recent legal activities going on the following patents of Dutrebis.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 09 Mar, 2022 US7820660
Payment of Maintenance Fee, 12th Year, Large Entity 09 Dec, 2021 US7754731
Payment of Maintenance Fee, 12th Year, Large Entity 16 Mar, 2020 US7435734
Payment of Maintenance Fee, 12th Year, Large Entity 16 Oct, 2018 US7217713
Payment of Maintenance Fee, 12th Year, Large Entity 12 Jun, 2018 US7169780
Payment of Maintenance Fee, 8th Year, Large Entity 13 Mar, 2018 US7820660
Payment of Maintenance Fee, 8th Year, Large Entity 15 Dec, 2017 US7754731
Post Issue Communication - Certificate of Correction 30 Mar, 2011 US7169780
Record a Petition Decision of Granted for Patent Term Adjustment after Issue 25 Jan, 2011 US7169780
Adjustment of PTA Calculation by PTO 25 Jan, 2011 US7169780

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Dutrebis is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Dutrebis's family patents as well as insights into ongoing legal events on those patents.

Dutrebis's Family Patents

Dutrebis has patent protection in a total of 44 countries. It's US patent count contributes only to 13.2% of its total global patent coverage. 12 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Dutrebis.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Dutrebis's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 11, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Dutrebis Generics:

There are no approved generic versions for Dutrebis as of now.

Alternative Brands for Dutrebis

Dutrebis which is used for managing HIV-1 infection., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Gilead Sciences Inc
Descovy Used for managing and treating HIV infection.
Msd Sub Merck
Isentress Hd Used for treating HIV infection.





About Dutrebis

Dutrebis is a drug owned by Merck Sharp And Dohme Corp. It is used for managing HIV-1 infection. Dutrebis uses Lamivudine; Raltegravir Potassium as an active ingredient. Dutrebis was launched by Merck Sharp Dohme in 2015.

Approval Date:

Dutrebis was approved by FDA for market use on 06 February, 2015.

Active Ingredient:

Dutrebis uses Lamivudine; Raltegravir Potassium as the active ingredient. Check out other Drugs and Companies using Lamivudine; Raltegravir Potassium ingredient

Treatment:

Dutrebis is used for managing HIV-1 infection.

Dosage:

Dutrebis is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
150MG;EQ 300MG BASE TABLET Discontinued ORAL